- Home
- BLNK vs PRQR Comparison
BLNK vs PRQR Comparison
Compare BLNK & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- PRQR
- Stock Information
- Founded
- BLNK 2009
- PRQR 2012
- Country
- BLNK United States
- PRQR Netherlands
- Employees
- BLNK N/A
- PRQR N/A
- Industry
- BLNK Industrial Specialties
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- PRQR Health Care
- Exchange
- BLNK Nasdaq
- PRQR Nasdaq
- Market Cap
- BLNK 295.1M
- PRQR 309.5M
- IPO Year
- BLNK N/A
- PRQR 2014
- Fundamental
- Price
- BLNK $1.53
- PRQR $3.62
- Analyst Decision
- BLNK Buy
- PRQR Strong Buy
- Analyst Count
- BLNK 7
- PRQR 4
- Target Price
- BLNK $5.64
- PRQR $7.13
- AVG Volume (30 Days)
- BLNK 5.4M
- PRQR 635.3K
- Earning Date
- BLNK 11-07-2024
- PRQR 11-07-2024
- Dividend Yield
- BLNK N/A
- PRQR N/A
- EPS Growth
- BLNK N/A
- PRQR N/A
- EPS
- BLNK N/A
- PRQR N/A
- Revenue
- BLNK $138,728,000.00
- PRQR $20,506,357.00
- Revenue This Year
- BLNK $6.03
- PRQR $298.83
- Revenue Next Year
- BLNK $30.95
- PRQR N/A
- P/E Ratio
- BLNK N/A
- PRQR N/A
- Revenue Growth
- BLNK 15.13
- PRQR 306.68
- 52 Week Low
- BLNK $1.48
- PRQR $1.18
- 52 Week High
- BLNK $4.48
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- BLNK 37.11
- PRQR 54.60
- Support Level
- BLNK $1.48
- PRQR $3.57
- Resistance Level
- BLNK $1.62
- PRQR $3.70
- Average True Range (ATR)
- BLNK 0.13
- PRQR 0.22
- MACD
- BLNK -0.04
- PRQR -0.08
- Stochastic Oscillator
- BLNK 7.35
- PRQR 18.06
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.